|
HUE040323T2
(hu)
|
2012-12-21 |
2019-02-28 |
Epizyme Inc |
PRMT5-inhibitorok és alkalmazásaik
|
|
CA2894157A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US9908887B2
(en)
|
2012-12-21 |
2018-03-06 |
Epizyme, Inc. |
PRMT5 inhibitors and uses thereof
|
|
JP2016505001A
(ja)
|
2012-12-21 |
2016-02-18 |
エピザイム，インコーポレイティド |
Ｐｒｍｔ５阻害剤およびその使用
|
|
EP2935243B1
(en)
|
2012-12-21 |
2018-03-14 |
Epizyme, Inc. |
Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
|
|
US9120757B2
(en)
|
2013-03-14 |
2015-09-01 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
US9133189B2
(en)
|
2013-03-14 |
2015-09-15 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
WO2014144659A1
(en)
|
2013-03-14 |
2014-09-18 |
Epizyme, Inc. |
Pyrazole derivatives as prmt1 inhibitors and uses thereof
|
|
AU2014236146B2
(en)
|
2013-03-14 |
2018-05-17 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
EP2970137A1
(en)
|
2013-03-14 |
2016-01-20 |
Epizyme, Inc. |
Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
|
|
EP2970181B1
(en)
|
2013-03-14 |
2017-06-07 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
EP2970266B1
(en)
|
2013-03-15 |
2018-01-31 |
Epizyme, Inc. |
1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
|
|
CN105228997B
(zh)
|
2013-03-15 |
2018-03-27 |
Epizyme股份有限公司 |
Carm1抑制剂及其用途
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
JP2017530940A
(ja)
|
2014-08-04 |
2017-10-19 |
エピザイム，インコーポレイティド |
Ｐｒｍｔ５阻害剤およびその使用
|
|
WO2017070089A1
(en)
|
2015-10-19 |
2017-04-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US20170145025A1
(en)
|
2015-11-19 |
2017-05-25 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
LT3394033T
(lt)
|
2015-12-22 |
2021-03-10 |
Incyte Corporation |
Heterocikliniai junginiai, kaip imunomoduliatoriai
|
|
US20170320875A1
(en)
|
2016-05-06 |
2017-11-09 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US20170342060A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
HRP20221030T1
(hr)
|
2016-06-20 |
2022-11-11 |
Incyte Corporation |
Heterociklički spojevi kao imunomodulatori
|
|
WO2018013789A1
(en)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
|
CA3042700A1
(en)
|
2016-11-07 |
2018-05-11 |
University Of Massachusetts |
Therapeutic targets for facioscapulohumeral muscular dystrophy
|
|
JP7149276B2
(ja)
|
2016-12-22 |
2022-10-06 |
インサイト・コーポレイション |
Ｐｄ－ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５－ｃ］ピリジン誘導体
|
|
BR112019012993A2
(pt)
|
2016-12-22 |
2019-12-03 |
Incyte Corporation |
derivados de benzo-oxazol como imunomoduladores
|
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
EP3558963B1
(en)
|
2016-12-22 |
2022-03-23 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
WO2018119236A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
ES2788856T3
(es)
|
2017-03-20 |
2020-10-23 |
Forma Therapeutics Inc |
Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
|
|
MX2019013954A
(es)
|
2017-05-25 |
2020-08-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras.
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
|
|
MY210070A
(en)
|
2018-03-30 |
2025-08-25 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
PT3790877T
(pt)
|
2018-05-11 |
2023-05-10 |
Incyte Corp |
Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1
|
|
KR20210045998A
(ko)
*
|
2018-08-01 |
2021-04-27 |
아락세스 파마 엘엘씨 |
헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법
|
|
ES2989438T3
(es)
|
2018-09-19 |
2024-11-26 |
Novo Nordisk Healthcare Ag |
Activación de la piruvato cinasa R
|
|
WO2020061378A1
(en)
|
2018-09-19 |
2020-03-26 |
Forma Therapeutics, Inc. |
Treating sickle cell disease with a pyruvate kinase r activating compound
|
|
CA3144344A1
(en)
|
2019-06-28 |
2020-12-30 |
Als Therapy Development Institute |
Inhibition of dipeptide repeat proteins
|
|
TW202115059A
(zh)
|
2019-08-09 |
2021-04-16 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
|
|
MA57202B1
(fr)
|
2019-09-19 |
2025-09-30 |
Novo Nordisk Health Care Ag |
Compositions d'activation de la pyruvate kinase r (pkr)
|
|
BR112022005826A2
(pt)
|
2019-09-30 |
2022-06-21 |
Incyte Corp |
Compostos de pirido[3,2-d]pirimidina como imunomoduladores
|
|
BR112022009031A2
(pt)
|
2019-11-11 |
2022-10-11 |
Incyte Corp |
Sais e formas cristalinas de um inibidor de pd-1/pd-l1
|
|
EP4121070A4
(en)
*
|
2020-03-18 |
2024-05-22 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer by inhibiting carm1
|
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
|
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
|
MX2023005362A
(es)
|
2020-11-06 |
2023-06-22 |
Incyte Corp |
Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|